secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0000879169-25-000100
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte Q2 2025 revenue up 16% to $1.216B; raised Jakafi and oncology guidance
-----------------------------------------------------------------------------

- Total revenues $1.216B (+16% YoY); net product rev $1.059B (+17% YoY). GAAP EPS $2.04 diluted, vs $(2.04) loss a year ago.
- Jakafi net rev $764M (+8%); full-year guidance raised to $3.0-3.05B (prev $2.95-3.0B). Opzelura $164M (+35%).
- Niktimvo launch strong with Q2 rev $36M; other oncology guidance raised to $500-520M (prev $415-455M).
- New CEO Bill Meury appointed June 26, 2025 upon retirement of Hervé Hoppenot.
- Novartis royalty dispute settled; Jakafi royalty rate reduced by 50% starting Jan 1, 2025; $280M paid in settlement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/0000879169-25-000100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/incy-20250729.htm
  HTML page:      https://secwatch.observer/filing/0000879169-25-000100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer